Overview
Winrevair is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with pulmonary arterial hypertension (PAH), also known as World Health Organization (WHO) Group 1 pulmonary hypertension. It is indicated to improve exercise capacity and WHO functional class, and to reduce the risk of clinical worsening events such as hospitalization for PAH, lung transplantation, or death. Winrevair is also known by its drug name, sotatercept-csrk.

Winrevair is an activin signaling inhibitor, a type of medication that helps restore balance to certain growth factors involved in blood vessel function. By doing this, it can reduce thickening in the lung arteries, improve blood flow, and ease strain on the heart.

How do I take it?
Prescribing information states that Winrevair is given as a subcutaneous (under the skin) injection. The starting dose is typically given every three weeks, with a target dose reached over time. Blood tests are required before each of the first five doses — or longer if needed — to monitor hemoglobin and platelet levels. Winrevair should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Winrevair include infections, nosebleeds, telangiectasia (small widened blood vessels), diarrhea, headache, rash, increased hemoglobin, dizziness, erythema (skin redness), and gum bleeding.

Rare but serious side effects may include erythrocytosis (increased red blood cell count), which can raise the risk of blood clots and hyperviscosity syndrome (thickened blood); severe thrombocytopenia (low platelet count), which can increase bleeding risk; and serious bleeding events, especially in people taking prostacyclin or blood thinners.

Winrevair may also harm an unborn baby and impair fertility for both males and females.

For more information about this treatment, visit:

Winrevair (Sotatercept-Csrk) for Injection, for Subcutaneous Use)—Merck Sharp & Dohme